IMPACT OF UNDIAGNOSED PREDIABETES ON PHOSPHODIESTERASE TYPE 5 INHIBITORS RESPONSE IN MEN WITH ERECTILE DYSFUNCTION

被引：0
|
作者：
Capogrosso, P. [1 ]
Boeri, L. [2 ]
Ventimiglia, E. [2 ]
Cazzaniga, W. [2 ]
Pozzi, E. [3 ]
Schifano, N. [2 ]
Chierigo, F. [2 ]
Abbate, C. [2 ]
Montanari, E. [4 ]
Montorsi, F. [2 ]
Salonia, A. [2 ]
机构：
[1] Osped San Raffaele, IRCCS, Unit Urol, Milan, Italy
[2] Osped San Raffaele, Milan, Italy
[3] San Raffaele Univ, Milan, Italy
[4] Osped Policlin, Milan, Italy
来源：
JOURNAL OF SEXUAL MEDICINE | 2019年 / 16卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PO-01-014
引用
收藏
页码：S52 / S53
页数：2
相关论文
共 50 条
  • [1] Undiagnosed prediabetes status is associated with a reduced effectiveness of phosphodiesterase type 5 inhibitors in men with erectile dysfunction
    Boeri, Luca
    Capogrosso, Paolo
    Ventimiglia, Eugenio
    Pozzi, Edoardo
    Chierigo, Francesco
    Belladelli, Federico
    Zuabi, Rani
    Schifano, Nicolo
    Abbate, Costantino
    Deho, Federico
    Montanari, Emanuele
    Montorsi, Francesco
    Salonia, Andrea
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2020, 32 (04) : 393 - 400
  • [2] Undiagnosed prediabetes status is associated with a reduced effectiveness of phosphodiesterase type 5 inhibitors in men with erectile dysfunction
    Luca Boeri
    Paolo Capogrosso
    Eugenio Ventimiglia
    Edoardo Pozzi
    Francesco Chierigo
    Federico Belladelli
    Rani Zuabi
    Nicolò Schifano
    Costantino Abbate
    Federico Dehò
    Emanuele Montanari
    Francesco Montorsi
    Andrea Salonia
    International Journal of Impotence Research, 2020, 32 : 393 - 400
  • [3] Phosphodiesterase type 5 inhibitors for erectile dysfunction
    Carson, CC
    Lue, TF
    BJU INTERNATIONAL, 2005, 96 (03) : 257 - 280
  • [4] Phosphodiesterase Type 5 Inhibitors and Erectile Dysfunction
    Whittaker, Catherine
    SA PHARMACEUTICAL JOURNAL, 2009, 76 (05) : 24 - 26
  • [5] Phosphodiesterase type 5 inhibitors and erectile dysfunction
    Whittaker, C.
    SOUTH AFRICAN FAMILY PRACTICE, 2010, 52 (03) : 207 - 210
  • [6] Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease
    Adesuyan, Matthew
    Jani, Yogini H.
    Alsugeir, Dana
    Howard, Robert
    Ju, Chengsheng
    Wei, Li
    Brauer, Ruth
    NEUROLOGY, 2024, 102 (04)
  • [7] Type 5 phosphodiesterase inhibitors: Curing erectile dysfunction
    Hellstrom, Wayne J. G.
    Kendirci, Muammer
    EUROPEAN UROLOGY, 2006, 49 (06) : 942 - 945
  • [8] The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction
    Ventimiglia, Eugenio
    Capogrosso, Paolo
    Montorsi, Francesco
    Salonia, Andrea
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (02) : 141 - 152
  • [9] The management of erectile dysfunction in men with diabetes mellitus unresponsive to phosphodiesterase type 5 inhibitors
    Cayetano-Alcaraz, Axel Alberto
    Tharakan, Tharu
    Chen, Runzhi
    Sofikitis, Nikolaos
    Minhas, Suks
    ANDROLOGY, 2023, 11 (02) : 257 - 269
  • [10] Improvement in Endothelial Function in Men Taking Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction
    Konstantinovsky, Alex
    Kuchersky, Nina
    Kridin, Khalaf
    Blum, Arnon
    AMERICAN JOURNAL OF MEDICINE, 2023, 136 (10): : 1041 - 1043
12345